For a long time, the cure for diabetes type 1 and type 2 has relied on agonizing insulin shots for patients or insulin infusion via mechanical pumps. Regarding this, experts have been creating artificial pancreatic beta cells with the he…
Description
External ventricular drainage provides a valuable minimally invasive solution for treating acute hydrocephalus and other conditions necessitating cerebrospinal fluid diversion. As a temporary measure, EVDs are placed directly into the brain's ventricles to drain excess CSF until stable reabsorption is restored.
Current market forecasts anticipate continued strong growth in EVD systems adoption over the coming years. A projected compound annual growth rate exceeding 7.8 percent reflects intensifying clinical needs as neurosurgery techniques advance and global disease burdens mount. Rates of hydrocephalus especially are considerable, impacting millions worldwide annually.
As a medical emergency, hydrocephalus presents serious risks such as elevated intracranial pressure susceptible to further neurological injury if untreated. Prompt CSF drainage through EVD placement is therefore paramount to stabilize patients for additional shunt or management procedures. Expanding access to care even in underserved regions will be key to making these lifesaving interventions more widely available.
Beyond hydrocephalus specifically, EVDs may also benefit head trauma, aneurysm and tumor resection patients experiencing intraventricular hemorrhage or edema. Their integration into post-surgical critical care pathways improves recovery outcomes. Streamlined multi-lumen catheters simplify simultaneous monitoring and drainage while protecting delicate ventricular ependyma from abrasion or occlusion.
From a technological perspective, biomaterials science continues yielding ever more bioabsorbable and anti-migrational materials lessening device complications. Nanocoatings that prevent clogging and infection could further expand applications to chronic settings. Overall market prospects appear bright as user-friendly EVD design and care delivery optimization enhance the quality and efficiency of complex neurosurgical cases.
Market Segmentation
This industry report offers market estimates and forecasts of the global market, followed by a detailed analysis of the application, patient group, and geography.
Application: intracerebral brain hemorrhage (ICH), subarachnoid hemorrhage, traumatic brain injury (TBI), others
Patient group: pediatric, adult
Geography: North America, Europe, Asia Pacific, Middle East and Africa, Latin America
Analyzing by application, traumatic brain injury (TBI) accounted for the dominant share of 38.1% of total market revenue in 2022. This segment is poised to chart the fastest expansion over the forecast period as well.
The rising incidence of TBI worldwide is the predominant factor driving acute EVD adoption. Per estimates, over 60 million new cases of TBI arising from falls, accidents and assaults are recorded annually across the globe.
TBI often leads to accumulation of excess cerebrospinal fluid in the brain due to hematomas or edema, heightening intracranial pressure. Acute EVD catheters provide crucial intervention by draining this fluid to stabilize patients. Usage helps mitigate secondary brain injury from elevated pressure, enabling recovery.
Based on geography, North America held the leading 35.6% market share in 2021. Dominance of North America stems from the high prevalence of neurological conditions like hemorrhagic and ischemic strokes, hydrocephalus, tumors requiring EVD intervention.
Established healthcare access and infrastructure also advantage the region, with specialized neuro-critical care units equipped with the latest technology. Reimbursement coverage for emergency neurosurgery procedures further propagates acute EVD placements. The U.S. remains at the epicenter of progress, with advanced new EVD devices receiving FDA approvals to meet evolving clinical needs.
Asia Pacific is forecast to grow at the most rapid clip globally, riding tailwinds like expanding healthcare expenditure, patient pool and neurosurgery infrastructure. Specifically China, Japan and India will present considerable opportunities as investment flows into facilities and equipment modernization.
Major Companies and Competitive Landscape
The market research report covers the analysis of key stake holders of the global acute EVD market. Some of the leading players profiled in the report include Fuji Systems Corporation, Integra LifeSciences Holdings Corporation, Medtronic plc, Natus Medical Incorporated, Neuromedex GmbH, Sophysa SA, Spiegelberg GmbH & Co. KG, among others. In this report, key players and their strategies are thoroughly analyzed to understand the competitive outlook of the market.
Scope of the Report
To analyze and forecast the market size of the global acute EVD market.
To classify and forecast the global acute EVD market based on application, patient group, geography.
To identify drivers and challenges for the global acute EVD market.
To examine competitive developments such as mergers & acquisitions, agreements, collaborations and partnerships, etc., in the global acute EVD market.
To identify and analyze the profile of leading players operating in the global acute EVD market.
Why Choose This Report
Gain a reliable outlook of the global acute EVD market forecasts from 2023 to 2029 across scenarios.
Identify growth segments for investment.
Stay ahead of competitors through company profiles and market data.
The market estimate for ease of analysis across scenarios in Excel format.
Strategy consulting and research support for three months.
Print authentication provided for the single-user license.